MDT — Medtronic plc

Q1 FY27 revenue rose 13.7% YoY to $9.756B, with broad-based growth across Cardiovascular, Neuroscience, Medical Surgical, and Diabetes, plus a raised FY27 organic growth guidance of 7.25%-7.75% and non-GAAP EPS guidance of $5.94-$6.00. FCF more than doubled YoY to $1.29B. Analysts remain at Buy/Moderate Buy with consensus targets in the $95-$100 range, and the forward P/E is low enough that sentiment has room to improve rather than being stretched.

Revenue growth has clearly accelerated over the last year: YoY growth went from roughly 2.5% in the Jan-2025 quarter to 6.6%, 8.4%, 9.9%, and 13.7% in the Jul-2026 quarter. The latest print includes roughly 5-6 points from an extra fiscal week, so underlying organic growth is still a solid high-single-digit pace. Operating margins are stable rather than expanding, ranging between roughly 15.9% and 19.7% over the past five quarters, with the latest quarter at 18.1%. This is an inflection story more than a margin-expansion story right now.

Medtronic is cheap relative to both its own history and large-cap medtech peers. The trailing P/E of 22.2x is distorted by GAAP charges; the more relevant forward P/E based on FY27 non-GAAP EPS of about $5.95 is roughly 15.2x at $90.65. That compares with a 5-year average P/E of 26.8x, a 5-year average P/S of 3.55x versus the current 3.09x, and a 3.5% dividend yield. Analysts also cite a roughly 25%-27% discount to large-cap medtech peers, which leaves room for multiple re-rating.

At $90.65, the market is paying only about 15.2x forward earnings, which is a mature/no-growth multiple rather than one pricing in meaningful expansion. If Medtronic executes on its 7.25%-7.75% organic growth guidance and hits roughly $5.94-$6.00 in FY27 EPS, even a modest re-rating to 17x forward earnings implies a price above $100. The risk is that the extra week inflates current compares and FY28 growth slows, but the low starting multiple plus a 3.5% dividend limit the downside.

As of 2026-09-01, RSI at 54.91 is neutral, not overbought or oversold. Price is 0.26% above the 20-day SMA, 5.75% above the 50-day SMA, and 0.97% above the 200-day SMA, so the intermediate trend is positive. However, the stock remains about 15% below its 52-week high of $106.33, suggesting a range-bound recovery rather than a fresh breakout. For a long-term investor, this looks like a reasonable accumulation zone rather than a momentum chase.

• Normalizing interest rates favor large-cap medtech with predictable revenue and strong free cash flow.
• Electrophysiology and structural heart procedure volumes, especially pulse field ablation, are secular growth drivers.
• Healthcare pricing and reimbursement pressure, particularly in the US and China, remains a background risk.
• Currency translation and the extra fiscal week distort reported growth comparisons, making organic metrics more important.
• Portfolio restructuring, including the anticipated MiniMed/Diabetes separation, could reshape capital allocation and margins.

• Continued commercial rollout of Affera mapping/ablation systems and Pi-Cardia structural heart technology.
• Final structural details and timeline for the MiniMed/Diabetes separation.
• Next quarterly earnings report, which will test whether the raised FY27 guidance is conservative.
• Dividend increases and continued S&P 500 Dividend Aristocrat status, reinforcing total-return appeal.

• The latest-quarter balance sheet data is anomalous (reported stockholders' equity and total assets are not usable), reducing confidence in the reported financial-health snapshot.
• FY28 will face a tough compare against the 53-week fiscal year, which could make reported growth look weaker.
• Competition in high-growth niches such as PFA, TAVR, and surgical robotics is intense, especially from Boston Scientific, Abbott, and J&J.
• Diabetes separation execution risk, including stranded costs, tax complexity, and management distraction.
• Medtech regulatory, recall, and litigation risks are permanent headline risks for a company this large.

Medtronic is an attractive long-term total-return candidate at $90.65: growth is accelerating, FCF generation is strong at $1.29B in the latest quarter, the dividend yields 3.5%, and the forward multiple is well below its own history and peer group. The principal caveats are a noisy balance-sheet data point and normal medtech competitive/execution risk, but the risk/reward is skewed favorably from here.

I applied a 17.2x forward P/E multiple to the midpoint of FY27 non-GAAP EPS guidance of $5.95, giving $102.34. That multiple is a discount to Medtronic's 5-year average P/E of 26.8x and to large-cap medtech peers, but a reasonable premium to the current ~15.2x forward multiple given 7.25%-7.75% organic growth, robust FCF, and a 3.5% dividend yield.